NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances

HONG KONG, Jun 12, 2025 - (ACN Newswire via SeaPRwire.com) - At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented new results findings on both NEFECON® (budesonide delayed release capsules), the world’s first and only approved therapy that directly targets the underlying cause of IgA nephropathy (IgAN), and EVER001, a next-generation covalent reversible BTK inhibitor. The latest results provide robust evidence for NEFECON®’s efficacy across the full disease spectrum and reinforce its foundational role in the emerging IgAN treatment strategy: “Treat the Cause, Treat Early, Treat All”. The nine studies covered biomarker-based prediction, treatment outcomes across various diagnostic timelines and baseline kidney function levels, long-term treatment durability, and mechanistic insights.Two studies further validated the critical role of NEFECON® in targeting the underlying mechanisms of IgA nephropathy (IgAN), reinforcing its position as the first-line etiological treatment for the disease. One study, based on the "Four-Hit" hypothesis, demonstrated that NEFECON® significantly impacts the first three pathogenic steps, ultimately reducing the risk of kidney function deterioration by 50%. Another study found that reductions in pathogenic Gd-IgA1 and polymeric IgA levels during the first two months of treatment closely correlated with improvements in proteinuria, suggesting their potential as predictive biomarkers to guide treatment.Two additional studies confirmed the clinical benefits of “Treat Early” with NEFECON®. A subanalysis of the NefIgArd study showed that patients who began treatment within six months of diagnosis experienced greater kidney protection and more significant reductions in proteinuria compared to those diagnosed earlier. This highlights the importance of early intervention to slow disease progression and achieve better long-term outcomes. Another prospective study supported this finding, showing that earlier treatment may more effectively reduce pathogenic immune factors and control inflammation, potentially preventing disease relapse or irreversible progression.Finally, two studies provided strong clinical evidence supporting NEFECON®’s “Treat All” strategy by confirming its broad applicability across different patient types. A subanalysis of the NefIgArd study found that NEFECON® effectively reduced proteinuria and preserved kidney function across all baseline eGFR levels. A separate multicenter study showed that patients with active pathological changes, such as endocapillary hypercellularity or crescent formation, experienced even more pronounced improvements in proteinuria and delayed disease progression.NEFECON® is the first and only fully approved etiological treatment for IgAN in China, the U.S., and Europe. It has been included in the KDIGO 2024 Clinical Practice Guideline For The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV) (public review draft). With updated data presented at ERA 2025, NEFECON® further solidified its position as a first-line cornerstone therapy, demonstrating a clear mechanism of action, sustained long-term benefits, and suitability for a wide range of patients. As NEFECON® continues to gain approvals across global markets, expand reimbursement coverage in China, and advance in tandem with diagnostic tools such as the Gd-IgA1 diagnostic kit under development, Everest Medicines is building a comprehensive “diagnosis-treatment-monitoring” ecosystem. This integrated approach is designed to shift IgAN management from symptomatic support toward precise, long-term disease control.In parallel, Everest Medicines’ proprietary next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, EVER001, was featured in a focused oral presentation at the 62nd Congress of the European Renal Association (ERA 2025). EVER001 has best-in-class potential for the treatment of primary membranous nephropathy (pMN) and other autoimmune kidney diseases such as IgAN, MCD, FSGS, and LN, targeting a global patient population of over 10 million. As no drug is currently approved for pMN, EVER001 offers a promising new option. Preliminary results from the ongoing Phase 1b/2a trial show that EVER001 is well tolerated and demonstrates strong clinical and immunological responses, including reductions in proteinuria and anti-PLA2R autoantibodies. The study also includes long-term follow-up data, supporting its potential in chronic disease management. Everest Medicines is continuing to expand clinical research to gather more data across patient groups and longer treatment durations.This advancement complements NEFECON® and exemplifies Everest Medicines’ “dual-engine” strategy, which combines in-licensed and internally developed innovations to broaden its kidney disease pipeline. Together, NEFECON® and EVER001 empower Everest Medicines to build a precise and durable kidney disease management ecosystem, accelerating global expansion and providing patients with accessible, effective treatment options. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million ACN Newswire

JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million

KEY HIGHLIGHTS- Revenue up by 20.7% to HK$782.3 million- Gross profit increased by 22.4% to HK$413.7 million- Consolidated profit attributable to equity shareholders grew by 51.2% to HK$197.3 million- The Board recommends a final dividend of HK11.5 cents per share- Flagship proprietary brands Ho Chai Kung, Po Chai Pills, and Flying Eagle Woodlok Oil delivered robust growth through effective brand management campaigns- Concentrated Chinese medicine granules (“CCMG”) remained resilient, providing a steady contribution to overall business performanceHONG KONG, Jun 12, 2025 - (ACN Newswire via SeaPRwire.com) - JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the "Group"), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the annual results of the Group for the year ended 31 March 2025 ("FY2025" or the "Reporting Period").Despite a lackluster retail environment in Hong Kong, JBM Healthcare delivered a robust financial and operational performance in FY2025. Revenue from the branded healthcare business rose by 20.7% year-on-year to HK$782.3 million. Gross profit grew by 22.4% to HK$413.7 million, while consolidated profit attributable to equity shareholders surged 51.2% to HK$197.3 million.This significant increase in consolidated profit attributable to equity shareholders was driven by robust sales of flagship brands - including Ho Chai Kung, Po Chai pills, and Flying Eagle Woodlok Oil, complemented by the resilient performance of its CCMG business. These strong results underscore the effective execution of the Group’s integrated sales and marketing strategies, and its strategic foresight in capturing growth opportunities in the branded consumer healthcare market across Hong Kong, Macau, and major cities in the Greater Bay Area.The Board recommends a final dividend of HK11.5 cents per share. Including the interim dividend of HK5.5 cents per share already paid, the total dividend for FY2025 will be HK17.0 cents per share.Solid Performance Across Core SegmentsIn the branded medicines business, sales revenue recorded strong growth of 43.2%, propelled by Ho Chai Kung’s sustained market momentum. Ho Chai Kung successfully expanded its market penetration through precisely targeted marketing initiatives that broadened its consumer base while simultaneously reinforcing brand recognition.Sales in the proprietary Chinese medicines segment grew by 5.0% against the backdrop of softened local retail sentiment of Chinese medicines and herbs, driven by the momentum of flagship brands Po Chai Pills and Flying Eagle Woodlok Oil, alongside the resilient performance of the CCMG business. Po Chai Pills enhanced brand visibility through sustained TVC placements and title sponsorship of popular television programs. Meanwhile, Flying Eagle Woodlok Oil reinforced its market position with an integrated campaign themed “Flying Eagle – The Real Master’s Choice”, highlighted by a viral “Flying Eagle Bro” billboard at Tsim Sha Tsui Star Ferry Pier, which tripled brand awareness.In the health and wellness products segment, revenue increased by 44.9%, driven by the steady growth of Oncotype DX Breast Recurrence Score Test (“Oncotype DX”), along with the expansion of our product portfolio and enhanced marketing efforts to meet consumer healthcare demands of the mass market. Oncotype DX has gained increasing recognition among healthcare professionals in Hong Kong and Macau.Capturing the Growth Potential of Cross-Border E-Commerce and TCM SectorThe Group has made steady progress in expanding its online presence on cross-border e-commerce platforms as well as strategically positioned to capitalise on the growing traditional Chinese medicine (“TCM”) sector in Hong Kong and the Greater Bay Area. The Group’s flagship stores on Tmall Global and JD.com have performed strongly, with Ho Chai Kung ranking among the top 10 overseas medicines during the 2024 Double 11 sales event. To drive sustainable growth, the Group is also diversifying into new categories while enhancing both its B2B and B2C sales networks.Strategic Acquisition of Tin Hee TongIn April 2025, the Group completed the acquisition of a 90% stake in Tin Hee Tong Medicine Factory, Limited, whose flagship product, Tin Hee Tong Tin Hee Pills, is a well-recognised brand in Hong Kong and mainland China, particularly among female consumers for its efficacy in regulating the menstrual cycle and supporting reproductive health. The acquisition expands the Group’s proprietary Chinese medicine portfolio and creates synergies by integrating Tin Hee Tong’s brand with the Group’s manufacturing and marketing strengths. Leveraging its expertise in brand management, the Group will launch a comprehensive marketing campaign to boost awareness, enhance engagement, and broaden distribution.Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, commented, “Amid the challenging retail environment, we delivered strong financial and operational performance, driven by our robust portfolio, the enduring appeal of our flagship brands, and our unwavering focus on operational excellence.”“Looking ahead, we remain committed to disciplined growth and operational excellence. With rising health awareness, increasingly sedentary lifestyles, and an ageing population continuing to fuel demand, we are well-positioned to capitalise on growth opportunities in the consumer healthcare sector. We will continue to sharpen our brand management capabilities, strengthen our core brand equity, expand our product offerings, and extend our market reach.”About JBM (Healthcare) Limited (Stock Code: 2161)JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and other select countries. The Group is a distinctive player in the sector with marketing expertise and heritage in pharmaceuticals that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Tin Hee Tong Tin Hee Pills, Flying Eagle Woodlok Oil), Tong Tai Chung Woodlok Oil, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.
More
10 winners selected at 8th edition of Start-up Express ACN Newswire

10 winners selected at 8th edition of Start-up Express

- On the Final Pitching Day of Start-up Express, 10 winners were selected, with xxx and AniTech Limited receiving the ESG Award and the My Favourite Start-up Award respectively- More than 200 industry players attended, helping start-ups to establish connections and increase exposure, and continue to promote Hong Kong's entrepreneurial ecosystem- Majority of the 10 winners are health tech start-ups, while others represented sectors such as green tech, smart city and AI SolutionsHONG KONG, Jun 12, 2025 - (ACN Newswire via SeaPRwire.com) - 10 start-ups were selected as winners at the eighth edition of Start-up Express, an entrepreneurship development programme organised by the Hong Kong Trade Development Council (HKTDC) which came to a successful conclusion. The ESG Award was presented to Green Vigor Limited in recognition of the best sustainable and socially impactful business solution, and AniTech Limited won the My Favourite Start-up Award as determined through audience live polling. The 10 start-ups will participate in a series of local and overseas business events organised by HKTDC to develop their profiles through building connections, exploring markets, seeking partners and enhancing brand awareness.HKTDC is fully committed to supporting and promoting the development of start-ups, helping them to expand into Mainland and international markets to showcase Hong Kong’s strengths in innovation and technology.Iris Wong, Director of Merchandise Trade and Innovation & External Relations of HKTDC said: “Start-up Express serves as the launchpad for Hong Kong’s brightest tech innovators. As HKTDC’s flagship start-up development programme, our mission is to help local tech start-ups build capability and connections, explore new markets, seek business and funding partners, and enhance their brand awareness. I am proud to share that we have already assisted 70 Hong Kong start-ups to scale-up in Hong Kong and expand into overseas markets since we first held Start-up Express in 2018. Many of these start-ups have achieved remarkable success, earning global awards, securing significant investments, and forming key business partnerships. This demonstrates how the HKTDC platform helps bring Hong Kong start-ups into the limelight and accelerate their success.”This year’s Start-up Express attracted more than 200 applications. The majority of the 10 winners are health tech start-ups while the rest represent green tech, smart city and AI solutions. Booths were also set up during the event enabling the Start-up Express finalists to showcase their businesses to all attendees and participants.Comprehensive range of networking and matching initiatives provided to winning start-upsThe 10 winners were chosen from 20 contestants during the final pitching round with each presenting their innovative business ideas and answering questions raised by the distinguished judging panel. The 10 winning start-ups are: ACTuWISE Limited, Decennium Platforms Limited, AniTech Limited, Digitoe Limited, CELLmeric Limited, RT Healthtech Co. Limited, Firefilm Group Limited, Albacastor Technology Limited, Entoptica Limited and Green Vigor Limited.Click here to download the list of winners and their company profiles.The HKTDC will arrange a series of exposure opportunities for the winning teams to interact with potential investors, buyers and partners.Judges praised the winners for their performance and awareness of market trendsOne of the judges, Herbert Chia, Senior Advisor of Alibaba Cloud (North APAC Region), said: “We are always surprised by the new start-ups in each year's awards. In the face of rapid AI development, many local start-ups have quickly incorporated AI into their business operations, showing that they are innovative, capable and also closely following the market trend.”Another judge, Jimmy Tao, Chairman of Hong Kong Startup Council, said: “The quality of this year's competition is high, with products and services covering different technologies, especially artificial intelligence, green tech and medical innovation. We are pleased to see the new generation of start-ups continue to break new grounds in innovation and technology, demonstrating their unlimited potential and creativity, thereby contributing to society’s advancement. Hong Kong's start-up scene continues to grow vigorously, with a record number of 4,694 start-ups last year, demonstrating Hong Kong's promising outlook and increasing attractiveness to do business and as an ideal to set up a start-up. We believe that this year's winning start-ups will gain valuable opportunities to expand their markets and build networks through Start-up Express.”Start-up Express helps start-ups secure investment and partnership opportunitiesStart-up Express provides extensive promotional opportunities for start-ups with winners able to take part in exhibitions in Mainland China and internationally, attend meetings with investors to learn more about the industry, market trends and investors’ preference.Libpet Tech, a Start-up Express winner in 2024, has recently completed a US$3 million seed funding, and the investment will be utilized for technology upgrades and international market expansion. Jojo Xu, CEO of Libpet Tech, said: "Participating in Start-up Express has given us more exposure and enhanced our brand awareness, as seen from the increased attention from potential customers and investors. We are grateful for the investors' confidence in our company. We will join hands with our public and private partners to integrate robotics into daily life and promote human-centric smart mobility.”The 4th Start-up Express International returns in December with global start-upsThe HKTDC has always given its full support to Hong Kong’s entrepreneurial ecosystem, helping to maintain the city’s status as a competitive business centre and hub for innovation. Start-up Express International was launched in 2022 for overseas early-stage start-ups to share the stage with local Start-up Express winners. The past three editions have attracted participants from around the world, including Australia, France, Germany, Japan, Korea, Turkey, Singapore, United Arab Emirates and the United States. The 4th Start-up Express International will return during Entrepreneur Day in December and the HKTDC will support the winners in setting up their businesses in Hong Kong and to explore the mainland and Greater Bay Area markets.Start-up Express: https://portal.hktdc.com/start-upexpress/Photo download: http://bit.ly/4jPwedcRepresentatives of the 10 winners of Start-up Express took a group photo with the judges and guests. Back row, from left to right: Herbert Chia, Senior Advisor of Alibaba Cloud (North APAC Region), Alan Cheung, Chairman & Managing Director of Grandion Group, Anthony Chan, CEO of Isola Capital, Iris Wong, HKTDC’s Director of Merchandise Trade and Innovation & External Relations, Matthias Knobloch, Managing Partner & CEO of Betatron Venture Group, Lui Tong, Chairman of PRD Angels and Jimmy Tao, Chairman of Hong Kong start-up CouncilStudents from local schools were invited to the Final Pitching Day of Start-up Express to present their innovative solutions. They were mentored by Sarah Tong, co-founder of Big Bang Academy, winner of Start-up Express 2023, who also presented the awardsMore than 200 industry players attended the Final Pitching Day of Start-up Express, giving the opportunity for start-ups to network with investors and business leadersBooths were also set up during the event, where finalists showcased their businesses to all attendees and participantsHKTDC Media Room: http://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Stanley So Tel: (852) 2584 4049 Email: stanley.hp.so@hktdc.orgKaty Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgSerena Cheung Tel: (852) 2584 4272 Email: serena.hm.cheung@hktdc.orgClayton Lauw Tel: (852) 2584 4472 Email: clayton.y.lauw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit:www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.
More

品質基石的守護者:檢測檢驗行業賦能高質量發展

香港, 2025年6月12日 - (亞太商訊 via SeaPRwire.com) - 改革開放以來,中國經濟實現了高速增長。 然而,隨著經濟的發展,如何保持長期的生產率增長成為關鍵問題。 2017年,中國共產黨第十九次全國代表大會首次提出"高質量發展",標誌著中國經濟由高速增長階段轉向高品質發展階段。 2023年2月,國務院印發《品質強國建設綱要》,強調國家品質基礎設施是實現高質量發展的重要保障。檢驗檢測行業作為高技術服務業,在推動國民經濟高質量發展方面發揮著重要作用。 據行業調查報告,中國獨立檢測檢驗行業市場總規模預計將從2022年的4,276億元增長至2027年的7,081億元,復合年增長率為10.6%。 其中,建設工程檢測檢驗行業是最大的子板塊,預計到2027年市場規模將達到約1,500億元。廣東省作為檢測檢驗行業的第一大省,通過「百千萬工程」加速基礎設施建設,促進了對建設工程檢測的需求。 粵西地區作為三線及以下縣市的檢測需求集中地,市場規模預計將從2023年的36億元增長至2028年的65億元,復合年增長率為12.7%。在粵西地區,廣東集信國控檢測認證技術服務中心股份有限公司(簡稱"集信國控")表現突出,前身為信宜市建設工程質量檢測站,成立於2000年,2024年在香港聯合交易所GEM板上市。 截至2024年12月,公司已獲得建設工程、環境、產品品質、食品、農林水畜漁等五個檢測領域41個檢測類別、3183+個檢測參數,在全省縣市級同類公司中名列前茅。受疫情影響,集信國控2022年的營業收入下降到1996萬人民幣,但公司憑藉清晰的戰略規劃和專業的檢測能力,業務迅速恢復增長。 2024年,公司營業收入達到5526萬人民幣,較2023年增長33.2%,毛利潤增長17.9%,凈利潤增長23.0%。 建設工程檢測檢驗板塊是公司最大的業務板塊,佔比超過50%。 公司現金流充足,2024年現金及現金等價物為99.86百萬元人民幣,並宣派了每股0.16港元的末期股息。集信國控正積極向綜合性檢測服務機構邁進,佈局交通檢測、水利檢測、消防檢測等新板塊。 2025年4月,收購了茂名市粵水工程檢測有限公司51%的股權,開拓水利檢測業務。 此外,公司還與佛山市高明區當地國企合資成立子公司,拓展區域市場。 借助香港上市平台,集信國控有望實現跨越式發展。在國家高質量發展和鄉村振興政策的雙重推動下,檢測檢驗行業將迎來高速發展。 集信國控憑藉國企公信力、技術實力和戰略佈局,為高新技術產業鏈供應鏈發展保駕護航,提升行業服務水準和國際競爭力。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
健倍苗苗二零二五財年全年業績表現亮眼 純利飆升51.2%至1.97億港元 ACN Newswire

健倍苗苗二零二五財年全年業績表現亮眼 純利飆升51.2%至1.97億港元

業績亮點- 收益增長20.7%至7.8億港元- 毛利上升22.4%至4.1億港元- 權益持有人應佔綜合溢利增長51.2%至1.97億港元- 董事會建議派發末期股息每股11.5港仙- 憑藉有效的品牌管理,旗艦品牌何濟公、保濟丸和飛鷹活絡油實現強勁增長- 濃縮中藥顆粒業務表現強韌,為整體業務表現提供穩定貢獻香港, 2025年6月12日 - (亞太商訊 via SeaPRwire.com) - 健倍苗苗(保健)有限公司(「健倍苗苗」或「公司」;股份代號:2161,連同其附屬公司統稱「集團」)為香港品牌保健品的領先營銷商及分銷商,集團今天公佈截至二零二五年三月三十一日止年度(「二零二五財年」或「報告期」)的全年業績。儘管香港零售環境疲軟,健倍苗苗於二零二五財年的財務與營運表現仍然出色。集團品牌醫療保健業務的收益按年增長20.7%至7.8億港元。毛利增長22.4%至4.1億港元,權益持有人應佔綜合溢利飆升51.2%至1.97億港元。權益持有人應佔綜合溢利大幅增長主要來自旗艦品牌的強勁銷售表現,當中包括何濟公、保濟丸與飛鷹活絡油,以及濃縮中藥顆粒業務的穩健表現。這一優異表現,顯示本集團成功落實整合的線上與線下營銷策略,並體現集團的前瞻性市場觸角,有效地把握香港、澳門及大灣區主要城市品牌消費健康市場增長機遇。董事會建議派發末期股息每股11.5港仙。包括已派付的中期股息每股5.5港仙,二零二五財年的股息總額為每股17.0港仙。各個核心業務表現卓越在何濟公持續銷售勢頭的帶動下,品牌藥分部的收益錄得43.2%的強勁增長。何濟公透過精準的市場營銷計劃擴大市場滲透率,成功擴大消費群體,同時進一步鞏固品牌的知名度。在本港中成藥及中藥材的零售銷售放緩的背景下,集團的品牌中藥分部仍實現5.0%的增長。此增長主要來自旗艦品牌保濟丸及飛鷹活絡油的強勁表現,以及濃縮中藥顆粒業務的穩健支持。保濟丸通過持續的電視廣告投放和冠名贊助電視人氣節目,進一步提高品牌知名度。與此同時,飛鷹活絡油透過以「飛鷹至係真王道」為主題的宣傳計劃強化市場地位,使其品牌知名度提升三倍,當中位於尖沙咀天星碼頭的「飛鷹哥」廣告板更成功引起熱議,迅速在網上瘋傳。健康保健品分部的銷售收益增長44.9%,動力來自安可待乳癌腫瘤基因檢測 (「Oncotype DX」)的穩健表現,加上產品組合擴展及加強推廣,有效回應大眾對健康產品日益增長的需求。Oncotype DX日益受到香港及澳門的醫療機構及醫護專業人士的認可。把握跨境電子商務及中醫藥市場的增長潛力集團在拓展線上業務方面取得穩步進展,尤其是跨境電子商務平台,同時策略性地進行部署,把握香港及大灣區持續增長的傳統中藥行業機遇。集團在天貓國際和京東的旗艦店表現強勁,何濟公於2024年雙11期間位列十大海外藥品暢銷榜。為了推動可持續增長,集團正豐富多元化產品組合,同時加強B2B和B2C的銷售網絡。策略性收購天喜堂二零二五年四月,集團完成收購天喜堂藥廠有限公司90%的股權,其旗艦產品「天喜堂天喜丸」於香港及中國內地享有極高的品牌知名度,特別受到女性消費者青睞,因其在調節女性生理週期及促進生殖健康方面具顯著功效。這項收購進一步豐富了集團的品牌中藥產品組合,並透過整合天喜堂品牌與集團現有的生產與營銷能力,創造顯著的協同效應。集團將憑藉在品牌推廣方面的豐富經驗,開展全方位的市場推廣計劃,以提升該品牌知名度,加強與消費者的互動,以及擴展分銷網絡,進一步拓展客戶基礎。健倍苗苗行政總裁黃一偉先生表示:「面對零售環境的種種挑戰,我們依然交出亮麗的財務及營運成績,這有賴於我們多元而穩健的產品組合、旗艦品牌持久的市場吸引力,以及我們對卓越營運的不懈追求。展望未來,我們將繼續秉持穩健增長與卓越營運的原則。隨著健康意識提升、久坐的生活模式普及以及人口老齡化持續帶動需求,我們已做好充分準備把握消費保健行業的增長機遇。我們將持續強化品牌管理能力,鞏固核心品牌價值,擴展產品組合,並擴大市場覆蓋範圍。」有關健倍苗苗(保健)有限公司 (股份代號:2161)健倍苗苗是設於香港的品牌醫療保健品推廣及分銷公司,產品據點遍及大中華、東南亞及其他選定國家。集團擁有豐富的行銷專業知識並具備深厚的製藥背景,秉承產品功效和品質至上的優良傳統,在行業內定位獨特,致力於滿足消費者的保健需要。作為本地領先的品牌醫療保健品運營商,集團擁有一廣泛系列品牌醫療保健品,包括品牌藥、品牌中藥及健康保健品,其中包括「保濟丸」、「何濟公止痛退熱散」、「天喜堂天喜丸」、「飛鷹活絡油」、「唐太宗活絡油」、「十靈油」、「鎮痛霸祛風活絡油」等家喻戶曉的傳統品牌。而自2021年 5月27日,集團獲納入 MSCI 香港微型股指數成份股。有關集團詳情,請瀏覽:www.jbmhealthcare.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.
More

耐賦康(R)與EVER001協同發力 雲頂新耀推動腎病治療進入精準管理新階段

香港, 2025年6月12日 - (亞太商訊 via SeaPRwire.com) - 在第62屆歐洲腎臟協會(ERA 2025)大會上,雲頂新耀(HKEX: 1952.HK)旗下全球首個對因治療IgA腎病藥物耐賦康®(布地奈德腸溶膠囊,NEFECON®)和新一代共價可逆BTK抑制劑EVER001都發佈了最新研究成果。其中,耐賦康®發佈9項最新研究成果,涵蓋生物標誌物預測、不同診斷時間和腎功能基線人群的療效評估、長期治療效果的持續性分析及作用機制驗證,全面印證其在「對因治療、盡早治療、全部治療」新管理策略下的廣泛適用性與長期臨床價值。兩項研究深入驗證了耐賦康®在干預IgA腎病致病機制中的關鍵作用,從機制層面明確支持耐賦康®作為IgAN首選「對因治療」方案的定位。其中一項研究基於「四重打擊」理論發現,耐賦康®可同時顯著作用於第一、第二、第三重打擊,最終實現腎功能惡化風險減少50%;另一項研究則顯示,治療早期(前兩個月)血液中致病性Gd-IgA1、多聚IgA水平的下降幅度與蛋白尿改善緊密相關,有望作為預測療效、指導治療的潛在生物標誌物。另外兩項研究成果證實,耐賦康®在「盡早治療」IgA腎病方面可實現具有更顯著臨床獲益。其中一項NefIgArd研究子分析顯示,確診時間不足6個月的IgA腎病患者在接受耐賦康®治療後,腎功能保護效果顯著好於確診時間更久的患者,蛋白尿改善幅度也更大。這意味著越早使用耐賦康®,越能延緩腎功能損傷,長期獲益也更大。另一項前瞻性研究也指出,早期治療不僅有助於減少致病性免疫因子的產生,還可能更有效控制炎症過程,避免病情反復或進入不可逆階段。還有兩項研究為耐賦康®「全部治療」策略提供了堅實的臨床依據,進一步確認耐賦康®對不同類型IgA腎病患者的廣泛適用性。一項NefIgArd研究子分析發現,不論患者起始時的腎功能水平高低,耐賦康®均能有效減少蛋白尿,並在各時間點維持腎功能穩定;另一項多中心研究表明,對於存在活動性病理改變(如毛細血管增生、新月體形成)的患者,耐賦康®同樣展現出更顯著的蛋白尿改善,並有效延緩疾病進展。作為全球唯一在中國、美國和歐洲獲得完全批准的IgA腎病對因治療藥物,耐賦康®不僅已被中外權威指南《2024版KDIGO IgA腎病和IgA血管炎臨床管理實踐指南(公開審查版)》,以及《中國成人IgA腎病及IgA血管炎臨床實踐指南(預審版本)》推薦,更通過本次ERA 2025大會的數據更新,再次鞏固了其機制優勢、適用人群廣度與長期療效可持續性。隨著全球多個國家批准上市、國內醫保覆蓋落地,以及與生物標誌物診斷工具(Gd-IgA1診斷試劑盒)的聯動開發推進,耐賦康®正在構建「診斷+治療+監測」一體化解決方案,引領IgA腎病從對症支持轉向精准對因治療的長期管理轉變。與此同時,雲頂新耀另一款核心管線,自主研發、擁有全球權益的新一代共價可逆BTK抑制劑EVER001也在本屆ERA大會上首次以集中口頭報告形式發佈其在原發性膜性腎病(pMN)中的階段性臨床研究資料,作為一款潛在「同類最佳」藥物,適用于原發性膜性腎病(pMN)、IgA腎病、微小病變病、FSGS和狼瘡性腎炎等多種自身免疫性腎臟疾病,覆蓋超1000萬患者潛在人群。該產品目前正在開展1b/2a期臨床研究,並已收集到更多患者的長期隨訪數據。初步結果顯示,EVER001在原發性膜性腎病中展現出良好的安全性、耐受性以及顯著的臨床緩解和免疫學緩解效果,進一步驗證了其作為治療蛋白尿型自身免疫性腎病新方案的潛力,未來將與耐賦康®形成機制和應用上的互補,拓展公司在腎病領域的產品佈局。耐賦康®與EVER001分別代表雲頂新耀在「授權引進」和「自主研發」方面的成果,體現「雙輪驅動」戰略在腎病這一藍海賽道的落地成效。兩款產品的協同推進,將助力公司構建更精准、長期的腎病管理體系,並加快全球拓展,為更多患者提供可及、可靠的治療選擇。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
This Technology is Conquering the World: Neutrinovoltaics Redefining Global Infrastructure ACN Newswire

This Technology is Conquering the World: Neutrinovoltaics Redefining Global Infrastructure

MUNICH, June 11, 2025 - (ACN Newswire via SeaPRwire.com) - A global energy transition is no longer optional-it's a necessity. But behind the scenes of solar and wind, another technology is entering industrial reality with far greater implications. Neutrinovoltaic technology, developed by the Neutrino® Energy Group, is not a distant concept. It's an operational platform for decentralized, 24/7 energy generation that is now expanding into mobility, aerospace, marine systems, and even high-security communications.Neutrinovoltaic Energy: Quiet, Infinite, Everywhere. Neutrinovoltaic technology converts the kinetic energy of neutrinos and other non-visible radiation into electricity. These omnipresent particles trigger atomic vibrations in a nanomaterial composed of alternating layers of graphene and doped silicon. The resulting resonant frequency is transformed into direct current. Far from ambient energy scavenging, this is a controlled, scalable generation method already powering advanced applications.Power Without Fuel: The Neutrino Power CubeThe Neutrino Power Cube is a compact, modular, and emission-free energy system delivering 5 to 6 kilowatts of continuous power. Weighing just 50 kilograms, it operates silently and autonomously, independent of weather or location. With no fuel, no combustion, and no grid connection required, the Cube holds the potential to decentralize energy infrastructure and become a cornerstone of clean, off-grid power generation worldwide.Autonomous Mobility: The Pi CarThe Pi Car applies neutrinovoltaic integration to electric vehicles. Instead of relying on traditional charging infrastructure, the Pi Car generates power continuously by embedding neutrinovoltaic materials into structural components like the body panels and roof. After an hour in ambient conditions, the vehicle can achieve up to 100 kilometers of additional range. Collaborators include Simplior Technologies for AI-based energy optimization, C-MET Pune for materials development, and SPEL Technologies for battery integration. The concept also supports retrofitting existing EV platforms to enhance range and energy independence.Flight Beyond Limits: Pi FlyPi Fly is Neutrino® Energy Group's aeronautics program, developing UAVs powered by onboard neutrinovoltaic systems and supercapacitor storage. Current prototypes include multirotor and flying wing models. The next phase targets autonomous VTOL aircraft for cargo delivery. Supporting this effort are mobile hydrogen refueling units, also powered by neutrinovoltaics, enabling off-grid aviation infrastructure.Maritime Transformation: Nautic PiNautic Pi brings this energy platform to the sea. Neutrinovoltaic-powered marine vessels are under conceptual development, allowing autonomous navigation without onboard fuel or external charging. The system is particularly suited for long-duration missions, remote operations, and submersible platforms.Communication Breakthrough: Project 12742Finally, Project 12742 explores neutrino-based data transmission. Unlike radio signals, neutrinos pass through dense materials with minimal interference. This allows for real-time, secure global communication even through rock, oceans, or planetary bodies-an enormous leap for high-security and interplanetary data systems.As governments and industries seek viable decarbonization paths, the Neutrino® Energy Group is no longer just proposing solutions-it's deploying them. With a multidisciplinary team of hundreds of researchers, engineers, and scientists from over 40 countries, strategic alliances, and a growing portfolio of high-impact applications, neutrinovoltaic technology isn't coming-it's already here. And it's conquering the world.Neutrino Energy GroupNeutrino Scientific BoardHolger Thorsten Schubart - CEOWebsite: www.neutrino-energy.comContact InformationHolger Thorsten SchubartCEO and member of the Scientific Advisory Boardoffice@neutrino-energy.com+493020924013Related Videohttps://www.youtube.com/watch?v=LiswrRR8H2QSOURCE: Neutrino Energy Group Copyright 2025 ACN Newswire via SeaPRwire.com.
More
這項技術正在征服世界:中微子光電技術正在重新定義全球基礎設施 ACN Newswire

這項技術正在征服世界:中微子光電技術正在重新定義全球基礎設施

尼黑,2025年6月11日 - (亞太商訊 via SeaPRwire.com) - 全球能源轉型已不再是可選項,而是勢在必行。然而,在太陽能和風能的背後,一項具有更深遠意義的技術正逐步走入工業現實。由 Neutrino® 能源集團開發的中微子光伏技術,不再是遙不可及的概念,而是已投入運行的分散式全天候能源生成平台,並正擴展至交通、航空航太、海洋系統,甚至高安全通信領域。中微子光伏技術通過將中微子及其他不可見輻射的動能轉化為電能來實現發電。這些無所不在的粒子會激發由石墨烯與摻雜矽交替層構成的奈米材料中的原子振動,產生共振頻率並被轉換為直流電。這種方式遠非環境能量「採集」,而是一種可控、可擴展的發電方法,已被用於多項先進應用。無需燃料的電力:中微子能源方塊中微子能源方塊是一種緊湊型、模組化、零排放的能源系統,可持續輸出5至6千瓦電力。設備僅重50公斤,運行時安靜、無需人工干預,且不受天氣與地理位置影響。它不依賴燃料、不產生燃燒、無需接入電網,具備去中心化能源基礎設施的潛力,有望成為全球潔淨、離網發電的重要支柱。自主移動出行:Pi CarPi Car將中微子光伏技術應用於電動車領域。它不依賴傳統充電基礎設施,而是透過將中微子光伏材料嵌入車身面板、車頂等結構部件中來實現持續發電。在常規環境條件下,僅需一小時即可為車輛帶來最多達100公里的額外續航里程。合作夥伴包括負責基於人工智慧的能源優化的 Simplior Technologies、從事材料研發的 C-MET Pune,以及提供電池整合方案的 SPEL Technologies。該技術理念還支援對現有電動車平台進行改造,以提升續航能力並實現能源獨立。突破飛行極限:Pi FlyPi Fly 是 Neutrino® 能源集團的航空項目,致力於開發由機載中微子光伏系統與超級電容儲能供能的無人飛行器(UAV)。目前的原型機包括多旋翼與飛翼機型。下一階段的目標是開發用於貨物運輸的自主垂直起降(VTOL)飛行器。為支持該項目,還配備了由中微子光伏技術供能的移動氫燃料補給裝置,以推動離網航空基礎設施的發展。海洋創新:Nautic PiNautic Pi 將這一能源平台拓展至海洋領域。採用中微子光伏技術驅動的船舶目前正處於概念開發階段,目標是實現無需燃料或外部充電的自主航行。該系統尤其適用於長時間任務、遠程作業及水下平台。通信突破:12742號專案最後,12742號專案探索基於中微子的數據訊號傳輸。與無線電訊號不同,中微子可輕易穿透密集介質,幾乎不受干擾。這項技術使得即便是在岩層、海洋,甚至是行星體之間,也能實現即時、加密的全球通信——為高安全等級通信及星際數據傳輸帶來巨大飛躍。在全球政府與產業尋找可行的脫碳途徑之際,Neutrino® 能源集團不再只是提出解決方案,而是在實際推進落地。該集團匯聚來自40多個國家的數百位研究人員、工程師與科學家,組建跨學科團隊,並與多方建立戰略聯盟,持續拓展高影響力應用領域。中微子光伏技術不再是未來的想像,它已經到來,正征服世界。Neutrino Energy GroupNeutrino 科學顧問委員會Holger Thorsten Schubart - 執行長網站:www.neutrino-energy.com聯絡資訊Holger Thorsten Schubart執行長暨科學顧問委員會成員office@neutrino-energy.com+493020924013相關影片https://www.youtube.com/watch?v=LiswrRR8H2Q來源:Neutrino Energy Group Copyright 2025 亞太商訊 via SeaPRwire.com.
More
英國國防部與通用原子航空系統公司簽署「保護者」支援合約 ACN Newswire

英國國防部與通用原子航空系統公司簽署「保護者」支援合約

聖地牙哥,2025年6月11日 - (亞太商訊 via SeaPRwire.com) - 英國國防部已與通用原子航空系統公司(GA-ASI)簽署一項關於「守護者」RG Mk1 遙控駕駛飛機系統的物流與維護支援合約。該合約被稱為「英國守護者可用性與支援方案」(UK PASS),將為由 GA-ASI 提供、目前由英國皇家空軍(RAF)操作的新型「守護者」遙控駕駛飛機系統提供持續支援。該型號的「守護者」遙控機基於 GA-ASI 的 MQ-9B SkyGuardian® 平台。照片來源:英國皇家空軍UK PASS 是一項直接商業銷售(Direct Commercial Sale)合約,涵蓋對「守護者」項目中遙控駕駛飛機(RPA)、可認證地面控制站以及模擬訓練系統的支援。「這份合約標誌著英國皇家空軍部署『守護者』遙控系統的重要里程碑,」通用原子公司歐洲 MQ-9B 副總裁克里斯・杜塞爾(Chris Dusseault)表示,「隨著 UK PASS 合約的簽訂,我們可以從測試和開發階段正式過渡到皇家空軍飛行員的操作訓練階段。」UK PASS 是通用原子公司「天空守護者全球支援方案」(SkyGuardian Global Support Solutions,簡稱 SGSS)的一部分,SGSS 為 MQ-9B 所有用戶提供支援。該方案採用共享的承包商後勤支援(Contractor Logistics Support, CLS)模式,將維護、供應管理及其他所需支援功能所涉人員、物資和間接資源統一整合,供所有客戶共同使用。此方式提升了效率,並為客戶降低了成本。「PASS 合約的簽訂是通用原子公司與英國國防部跨領域團隊三年來密切合作的成果,它將一個概念轉化為現實。我們為皇家空軍的『守護者』機隊打造了首個同類中的可持續支援方案,依托的是全球通用備件池中的承包商自有庫存。該合約不同於傳統的備件與維修合約,而是透過多客戶通用營運模式實現規模經濟,」英國皇家空軍無人機系統 3 組組長里奇・卡梅隆上校(Group Captain Rich Cameron)表示。通用原子公司的 MQ-9B 是目前全球最先進的遙控駕駛飛機系統,具備卓越的續航能力與作戰範圍。MQ-9B 包括「天空守護者」(SkyGuardian)與「海洋守護者」(SeaGuardian®)兩種型號,目前已向英國皇家空軍(即「守護者」項目)交付多架,並獲得來自加拿大、波蘭、日本海上保安廳、日本海上自衛隊、台灣、印度及美國空軍(用於特種作戰司令部支援)的訂單。MQ-9B 亦曾參與多項美國海軍演習,包括「北方利劍」(Northern Edge)、「整合作戰問題」(Integrated Battle Problem)及「聯合航行演訓」(Group Sail)。關於 GA-ASI通用原子航空系統公司(GA-ASI)是通用原子公司的子公司,致力於設計與製造成熟可靠的遠程駕駛航空系統(RPA)、雷達及電光與相關任務系統,包括 Predator® RPA 系列與 Lynx® 多模式雷達。GA-ASI 營運超過 800 萬飛行小時,提供具備長航時與任務能力的航空平台,並整合感測器與資料鏈系統,以實現持續態勢感知。公司亦研發多種感測器控制與圖像分析軟體,提供飛行員訓練與支援服務,並開發超材料天線。更多資訊,請造訪:www.ga-asi.com。Avenger、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian 和 SkyGuardian 均為通用原子航空系統公司在美國及其他國家/地區註冊的商標。聯絡資訊GA-ASI 媒體關係部asi-mediarelations@ga-asi.com(858) 524-8101來源:General Atomics Aeronautical Systems, Inc. Copyright 2025 亞太商訊 via SeaPRwire.com.
More
HKTDC Design Gallery x STICKYLINE present: “Love HK” Exhibition ACN Newswire

HKTDC Design Gallery x STICKYLINE present: “Love HK” Exhibition

HONG KONG, Jun 11, 2025 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) Design Gallery continues to champion original Hong Kong designs. The annual “Love HK” exhibition returns from 11 June to 6 July, in partnership with STICKYLINE, a prominent creative team in Hong Kong, and will debut their latest artwork, “The Carved Duo”, at the Design Gallery Wan Chai shop, featuring large-scale artistic paper sculptures that capture the essence of a traditional dragon and phoenix grand hall.Carved dragon and phoenix statues were iconic decorations in Hong Kong’s banquet halls during the 1970s. STICKYLINE reimagines these symbols through contemporary geometric paper sculptures, incorporating pixel-like grid patterns into the Design Gallery’s window. This artwork retains the auspicious meanings of the dragon and phoenix while refining their forms, exploring how cultural heritage can evolve within modern contexts.STICKYLINE’s co-founder Mic Leong said, “We are thrilled to collaborate with the HKTDC Design Gallery on the ‘Love HK’ exhibition. In line with the theme, we have created paper sculptures inspired by the traditional dragon and phoenix grand halls found in old restaurants which were used to symbolise the city’s economic boom and opulence. Although modern restaurants have phased out such designs, these motifs are resurfacing in unexpected ways, such as tattoo art, wedding backdrops, and avant-garde photography, reflecting younger generations’ reinterpretation of tradition. Through this piece, we aim to revive the collective memories of old-school restaurants and showcase Hong Kong's unique charm.”In addition to the dragon and phoenix installation, the main entrance of the Design Gallery features a playful paper sculpture of the word “HEY”. Soilworm Lai, Co-Founder, STICKYLINE, explained, “‘HEY’ is a phonetic nod to the word ' (double happiness)’. We aspire to merge modern elements with the traditional dragon and phoenix theme, offering a friendly greeting to visitors.”Curated selection of Hong Kong-themed productsDuring the exhibition, the Design Gallery will feature a curated selection of Hong Kong-themed products, including AMAZING STUDIO Neon Light Hong Kong Metal Badge Pin, CAMEL Modern Hong Kong Culture Glass Vacuum Flask, IRON WORKSHOP Hong Kong Silk Scarf Map, and PLAYFUL SOCKS Dragon Phoenix Happiness Socks.Share on social media for shopping discountVisitors can enjoy an additional 10% discount on purchases during the exhibition by taking photos of the exhibits and sharing these on social media, tagging @HKTDC Design Gallery.Design Gallery Love HK x STICKYLINE – “The Carved Duo” ExhibitionDate11 June – 6 July 2025VenueHKTDC Design GalleryG/F, Hong Kong Convention & Exhibition Centre, 1 Harbour Road, Wan Chai, Hong KongOpening hoursMonday – Sunday & Public Holidays: 10:30am – 7:30pmEnquiries2584 4146 / 2584 4149Websitehttps://hkdesigngallery.hktdc.com/Social MediaFacebook: www.facebook.com/HKTDC.DesignGalleryInstagram: www.instagram.com/hktdc_designgalleryPhoto download: https://bit.ly/4dXb9fzThe HKTDC Design Gallery annual “Love HK” exhibition returns from 11 June to 6 July, in partnership with STICKYLINE, a prominent creative team in Hong Kong, to debut their latest artwork, “The Carved Duo”, at the Design Gallery Wan Chai shop, featuring large-scale artistic paper sculptures that capture the essence of traditional dragon and phoenix grand hallSTICKYLINE, founded in Hong Kong by creative designers Mic Leong (left) and Soilworm Lai (right), creates unique, large-scale polyhedral sculptures that showcase the complexity of creative engineering, mathematics and geometric structuresCurated selection of Hong Kong-themed productsAMAZING STUDIONeon Light Hong Kong Metal Badge PinPrice: HK$78CAMELModern Hong Kong Culture Glass Vacuum FlaskPrice: HK$439IRON WORKSHOPHong Kong Silk Scarf MapPrice: HK$370KONSEPTRemote Control Block Hong Kong TramPrice: HK$799PLAYFUL SOCKSDragon Phoenix Happiness SocksPrice: HK$99YI-MINGPOLA Hong Kong Print Chinese Folding FanPrice: HK$168WebsiteHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Serena CheungAgnes WatTel: (852) 2584 4272Tel: (852) 2584 4554Email: serena.hm.cheung@hktdc.orgEmail: agnes.ky.wat@hktdc.orgAbout STICKYLINESTICKYLINE, founded in Hong Kong in 2011 by creative designers Mic Leong and Soilworm Lai, creates unique, large-scale polyhedral sculptures that showcase the complexity of creative engineering, mathematics and geometric structures. They transform two-dimensional planes into three-dimensional forms through a process of deconstruction and reconstruction. They have collaborated with international brands including Hermès, Ralph Lauren, and Mercedes-Benz.Discover more at: https://www.stickyline.hkAbout HKTDC Design GalleryEstablished in 1991, the Hong Kong Trade Development Council’s Design Gallery (DG) promotes Hong Kong’s creativity innovation in design. With two physical outlets in Hong Kong and Taobao and JD International online stores, DG helps Hong Kong brands connect and collaborate with buyers to grow and expand in Mainland China and beyond. The DG online shop also provides suppliers with local online sales channels. DG’s entry into the ASEAN market enables Hong Kong brands to connect with overseas consumers and buyers.Discover more at: https://hkdesigngallery.hktdc.com/About HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Blockpass partners with CryptoSwift to deliver global Travel Rule Compliance ACN Newswire

Blockpass partners with CryptoSwift to deliver global Travel Rule Compliance

HONG KONG, June 11, 2025 - (ACN Newswire via SeaPRwire.com) - Identity verification and regulatory compliance provider Blockpass is excited to announce a new partnership as it begins working with CryptoSwift OÜ, the Travel Rule compliance service, to enhance and simplify the process of meeting regulatory standards around the world. This endeavor will see CryptoSwift’s Travel Rule compliance measures added to Blockpass’ suite of regulatory solutions, enabling one-stop access to comprehensive compliance.Blockpass, the Safe Network for Crypto™, has pioneered reusable identities and crypto-native KYC/AML solutions. Its turnkey suite of compliance tools is designed to lower onboarding costs, automate remediation, prove humanity and protect against malicious actors, fraudulent activities, bots, and AI. Businesses can set up services quickly, test them for free, and start verifying users. With around one million verified identity profiles, Blockpass facilitates instant onboarding, and to date over a thousand businesses have taken advantage of this opportunity to benefit from Blockpass’ compliant network.Estonian-based CryptoSwift has been working to further crypto compliance since 2022, enabling companies to meet Travel Rule requirements whilst continuing to innovate. The solution focuses on simplicity, security, and efficiency with an easy-to-integrate API. CryptoSwift facilitates the secure transmission of required data between Virtual Asset Service Providers (VASPs) by automating compliance, providing real-time transaction monitoring whilst meeting both FATF guidelines and MiCA regulations, ensuring compliant transfers of digital assets."The Travel Rule is rapidly becoming an essential part of the compliance landscape as more and more countries around the world implement the FATF’s recommendations to secure the crypto space.” said Blockpass CEO Adam Vaziri. “We’re delighted to be working with CryptoSwift towards our mutual goals of facilitating compliance for those innovating or working in crypto.”“Partnering with Blockpass is a natural step forward in our mission to make regulatory compliance seamless for the crypto industry," said Indrek Ulst, Founder and CEO of CryptoSwift. “Blockpass shares our vision of reducing friction without compromising security or compliance. By combining our Travel Rule infrastructure with their leading KYC and AML solutions, we’re enabling crypto businesses to meet global regulatory standards with greater speed, confidence, and simplicity.”With this new partnership, Blockpass brings CryptoSwift’s services to its entire userbase and enables those seeking to comply with the vital Travel Rule recommendations. Through bringing all a company’s compliance needs to one place, Blockpass and CryptoSwift continue to work tirelessly to take the burden of regulatory compliance off the innovators in the crypto space whilst keeping them safe and secured against threats.To further support the Web3 industry, Blockpass has developed the Crypto Travel Rule Hub providing a comprehensive knowledge base, detailed country-specific regulatory insights, and a VASP-to-VASP network to help businesses navigate global compliance.About BlockpassEmbrace seamless compliance with Blockpass, the ultimate turnkey solution for KYC, KYB, and AML. Built by compliance veterans and crypto-natives, our cost-effective suite lets you automate processes, eradicate fraud, and onboard globally with confidence. Instantly activate compliant KYC/AML for DeFi, exchanges, token launchpads, and more. Leverage the Advanced KYC Bot™ for intelligent remediation, On-Chain KYC® for data-free anonymity, and Unhosted Wallet KYC™ to meet Crypto Travel Rule regulations. Navigate evolving standards with our dedicated Travel Rule Hub, a resource for global crypto compliance. Expand your reach effortlessly through our network of one million pre-verified users and three thousand businesses. Join industry leaders like Animoca Brands, Cardano, Polygon, and most crypto launchpads who all partner with Blockpass for trusted compliance and accelerated growth. Join the cutting edge of secure, streamlined onboardings.Learn more and engage the Blockpass team:Website: http://www.blockpass.orgTravel Rule Hub: https://www.blockpass.org/crypto-travel-hub/Email: sales@blockpass.orgAbout CryptoSwiftCryptoSwift is a compliance technology company delivering Travel Rule solutions for the crypto industry. Founded in 2022, CryptoSwift helps virtual asset service providers (VASPs), crypto asset service providers (CASPs), exchanges, and financial institutions meet evolving regulatory requirements such as FATF, MiCA, and TFR standards through a powerful, API-first platform designed for simplicity, security, and scalability. Backed by open-source protocols and led by fintech experts, CryptoSwift ensures compliant crypto transfers without borders or hassle.Whether you’re running an exchange or bridging crypto transfers across various blockchain technologies, CryptoSwift supports your growth with compliance you can trust.Join the CryptoSwift network to enable scalable crypto transactions and stay compliant.Learn more and connect with the CrypoSwift team:Website: https://cryptoswift.eu/Email: sales@cryptoswift.eu Copyright 2025 ACN Newswire via SeaPRwire.com.
More
New HKTDC Chairman Frederick Ma keen to promote Hong Kong as best partner for global enterprises ACN Newswire

New HKTDC Chairman Frederick Ma keen to promote Hong Kong as best partner for global enterprises

HONG KONG, Jun 9, 2025 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC)’s new Chairman Prof Frederick Ma met with media today, outlining the HKTDC’s strategic direction to help Hong Kong enterprises navigate global challenges and seize new opportunities.Prof Ma said: “The international trade landscape is turbulent, and enterprises urgently need to reassess their development strategies. As both a springboard for the country and an international hub, Hong Kong possesses the unique advantages of internal and external connectivity and is poised to play a pivotal role in the new trade landscape.”He pointed out that HKTDC will help Hong Kong businesses connect globally and turn challenges into opportunities. Through three strategic directions —1) reinforcing Hong Kong’s role as a superconnector and super value-adder to highlight its international status and deepen ties with global markets, 2) building a multinational supply chain management centre, and 3) promote trade digitalisation to position Hong Kong as the best partner for global enterprises, helping SMEs to stand out in an ever-changing world.The HKTDC will leverage its network of 51 offices globally and 49 Hong Kong business associations to support enterprises in exploring new markets and enhancing competitiveness. Prof Ma said: “Hong Kong has always been a city of opportunities. The HKTDC will stand side by side with Hong Kong businesses, seizing opportunities in an ever-changing world, integrating Hong Kong into national development and telling the good stories of Hong Kong and Mainland China.”Five directions to forge a new chapter for Hong Kong1.Advancing our strengths in internal and external connectivity and leveraging our global network, enhancing overseas visits and flagship promotions: Reviewing the HKTDC’s global network of 51 offices to reinforce our work in key markets and enhance Hong Kong’s international competitiveness. The HKTDC will continue organising more trade missions to tell the good stories of Hong Kong and Mainland China. A prime example is our flagship campaign Think Business, Think Hong Kong, which will be held in Milan, Italy in November.2.Optimising existing flagship events: By incorporating industry collaboration elements into the annual Asian Financial Forum (AFF), we will transform it into AFF Plus to facilitate connections between finance and the real economy, driving innovation, regional integration and sustainable development. For trade fairs, we will strengthen content related to global trends, including elements of robotics and higher education. Additionally, we will host new events targeting key markets, like the Middle East, inviting mainland enterprises to participate, to promote trade and investment cooperation between Hong Kong and countries in the Middle East region.3.Building an international supply chain management centre: In response to the trend of mainland industrial chains extending overseas, the HKTDC will actively position Hong Kong as a supply chain command centre to support mainland firms in going global.4.Driving the innovation engine and promoting trade digitalisation: The HKTDC will enhance existing support services, focusing on core elements of trade digitalisation to help SMEs leverage technologies - such as IOT, AI, blockchain and big data – to boost efficiency. In the long term, the HKTDC aims to position Hong Kong as a value chain centre, utilising technology, data analytics and collaborative networks to refine value chains for global enterprises, creating added value and addressing market changes and uncertainties.5.Explore long term demand for the convention and exhibition industry: The HKTDC will support the Hong Kong SAR Government in reviewing the needs of the convention and exhibition sector in the long term.Photo download: https://bit.ly/440xPHs HKTDC Chairman Prof Frederick Ma and Executive Director Margaret Fong met with media today to introduce the latest strategies for HKTDC to support SMEs and help them tackle business challengesHKTDC Chairman, Professor Frederick MaThink Business, Think Hong Kong Paris organised by the HKTDC was successfully held in Paris, France in 2023, attracting more than 1,300 participants. The event will be held in Milan, Italy this NovemberThe annual Asian innovation and technology event, InnoEX presents a range of low-altitude economy solutions, such as drones and aerial vehicles, to drive innovative developmentThe HKTDC hosts numerous major exhibitions and conferences in Hong Kong annually to foster trade collaboration. Pictured is this year’s Hong Kong International Jewellery Show held at the Hong Kong Convention and Exhibition CentreThe HKTDC has organised a delegation of Hong Kong enterprises to participate in the China International Import Expo for seven consecutive years. Last November, it led 52 Hong Kong companies to exhibit at the Hong Kong Product Pavilion and Hong Kong Service Pavilion. Moving forward, the HKTDC will continue to promote Hong Kong’s high-quality products and professional services to the mainland and international business communities.Media enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Serena CheungTel: (852) 2584 4272Email: serena.hm.cheung@hktdc.orgSunny NgTel: (852) 2584 4357Email: sunny.sl.ng@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
U.S. Polo Assn. Returns as Official Apparel and Jersey Partner for Chestertons Polo in the Park in Downtown London ACN Newswire

U.S. Polo Assn. Returns as Official Apparel and Jersey Partner for Chestertons Polo in the Park in Downtown London

West Palm Beach, FL, June 10, 2025 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official brand of the United States Polo Association (USPA), proudly served once again as the Official Apparel and Jersey Partner for Chestertons Polo in the Park, one of the world's largest and most iconic polo lifestyle festivals. Held June 6-8, 2025, at the historic Hurlingham Park in the heart of London, this year's edition welcomed over 30,000 attendees across three thrilling days of international polo, sport-inspired fashion, and family-friendly entertainment.U.S. Polo Assn. at Chestertons Polo in the ParkTeam Riyadh and Tournament MVP Cesar Crespo and Arkham Team Punta Cana’s Tommy Severn Battling for the Ball at Chestertons Polo in the Park Wearing the Iconic Double Horsement Logo From Apparel and Jersey Sponsor U.S. Polo Assn.As the Official Apparel and Jersey Partner, U.S. Polo Assn. outfitted all participating teams of the weekend, as well as staff uniforms. The brand also hosted an immersive on-site experience for event attendees, featuring a vibrant U.S. Polo Assn. merchandise tent showcasing official co-branded event apparel, a polo-inspired photo wall, and interactive brand models, along with contests and cap giveaways.Now in its 15th year, Chestertons Polo in the Park is the only polo event played in central London and continues to grow in prestige and popularity as Europe's largest three-day polo and lifestyle event with action-packed polo games, food festivals, luxury shopping, entertainment, and more. The highly anticipated weekend kicked off with International Day on Friday, as England faced Argentina, alongside six world-class polo teams representing different global cities, followed by Saturday's Ladies Day, and the culminating event on Sunday with Finals and Family Day, drawing crowds of polo enthusiasts from the U.K. and across the globe. Team Riyadh won the weekend's tournament against Akrham Team Punta Cana with a score of 10-5, and Cesar Crespo from Team Riyadh was awarded Tournament MVP."Chestertons Polo in the Park is a one-of-a-kind event that brings together the spirit of polo, our U.S. Polo Assn. brand, and the energy of London in a fun, stylish, and accessible way," said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the U.S. Polo Assn. brand. "Our sponsorship reinforces the authentic connection between our brand and the sport of polo while helping us further engage U.K. consumers in one of our most important and fastest-growing markets."The global, multi-billion-dollar U.S. Polo Assn. brand continues to expand across the United Kingdom with store openings at McArthurGlen's East Midlands and Cheshire Oaks and additional brick-and-mortar locations planned in the coming years. U.K. consumers can also explore the brand's latest sport-inspired styles for men, women, and children at www.uspoloassn.co.uk."As the strategic partner of U.S. Polo Assn. in the U.K., Chestertons Polo in the Park is an ideal platform to showcase our sport-inspired brand's connection to historic English polo," said Boo Jalil, CEO of Brand Machine Group, U.S. Polo Assn.'s U.K. licensing partner. "This annual celebration not only builds brand visibility in a meaningful way, but also highlights the fun, fashion-forward, and approachable spirit of U.S. Polo Assn."Set against the backdrop of one of polo's most historic venues - Hurlingham Park, where the sport was first played in 1874, the event reflects decades of tradition, including hosting the 1908 Olympic Polo Final and multiple Westchester Cup matches between the United States and England."U.S. Polo Assn. is the perfect fit for Chestertons Polo in the Park, and we value the continued support," said Rory Heron, Managing Director of Sportgate International, the founding organizer of the event. "The brand's meaningful connection to the game and globally recognized style brings authenticity, accessibility, and innovative activations to our spectacular annual celebration of sport and lifestyle in London."Photo Captions:1. Team Riyadh and Tournament MVP Cesar Crespo and Arkham Team Punta Cana's Tommy Severn Battling for the Ball at Chestertons Polo in the Park Wearing the Iconic Double Horsement Logo From Apparel and Jersey Sponsor U.S. Polo Assn.2. U.S. Polo Assn. Merchandise Pop-Up at Chestertons Polo in the Park3. Event Attendees Posing With Models of Official Apparel Sponsor U.S. Polo Assn.4. Chestertons Polo in the Park Player Noor Khadra Signing U.S. Polo Assn. Caps, Given Out at the Spectacular Three-Day Lifestyle Event5. Beautiful Chestertons Polo in the Park Guests Posing in U.S. Polo Assn. Caps, Given Out at the Spectacular Three-Day Lifestyle EventPhoto Credit: Jen DeberignyAbout U.S. Polo Assn.U.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. Historic deals with ESPN in the United States and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, NBA, and MLB, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global and digital growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ, as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world.For more information, visit uspoloassnglobal.com and follow @uspoloassn.About Brand Machine Group (BMG)BMG is an international leader in fashion innovation which has established itself as a vertical manufacturer and global licensing specialist with over four decades of industry experience. Partnering with recognized market leaders, BMG manages a seamless and collaborative process of designing, manufacturing, and delivering quality products while championing the DNA of a diverse portfolio of brands, spanning fashion, sports, outdoor, and homeware including adult fashion, kidswear, and accessories.BMG's portfolio of brands includes U.S. Polo Assn. Penfield, New Balance Kids, Duchamp, Jack Wills, Flyers American Born, Lee Kids, Peckham Rye, Wrangler Kids, Juicy Couture, Franklin & Marshall, Elle Junior and Ben Sherman. BMG reaffirms its commitment to upholding sustainable and ethical business practices by ensuring full transparency throughout its global supply chain, aligning with the ETI Base Code.Visit brandmachinegroup.com and follow @brandmachinegroup. For appointments, contact sales@brandmachinegroup.com.About Sportgate InternationalSportgate International is an international event management and sports marketing agency. Established in 2015, Sportgate International now owns events and consults with companies, luxury brands, world-class venues, tourism boards, and rights holders requiring sponsorship and event expertise. Sportgate International owns a portfolio of luxury events which encourages and enables the world's best brands, top companies, and individuals to further their corporate or personal objectives. The company also works with some of the most high-profile venues in the world, offering original content that enables networking and marketing to specific audiences.For more information, visit sportgateint.com.Contact InformationShannon StilsonVP, Sports Marketing and Mediasstilson@uspagl.com+001.561.227.6994Stacey KovalskyVP, Global PR and Communicationsskovalsky@uspagl.com+001.561.790.8036SOURCE: U.S. Polo Assn.Related ImagesU.S. Polo Assn. at Chestertons Polo in the ParkU.S. Polo Assn. Merchandise Pop-Up at Chestertons Polo in the ParkU.S. Polo Assn. at Chestertons Polo in the ParkEvent Attendees Posing With Models of Official Apparel Sponsor U.S. Polo Assn.U.S. Polo Assn. at Chestertons Polo in the ParkChestertons Polo in the Park Player Noor Khadra Signing U.S. Polo Assn. Caps, Given Out at the Spectacular Three-Day Lifestyle EventU.S. Polo Assn. at Chestertons Polo in the ParkBeautiful Chestertons Polo in the Park Guests Posing in U.S. Polo Assn. Caps, Given Out at the Spectacular Three-Day Lifestyle Event Copyright 2025 ACN Newswire via SeaPRwire.com.
More

爆款IPO前瞻:「香水第一股」穎通控股強勢登場!港股IPO再現黃金賽道 龍頭勢掀「嗅覺經濟」新浪潮

香港, 2025年6月10日 - (亞太商訊 via SeaPRwire.com) - 隨着港股IPO市場熱度回升,中國除品牌所有者之外最大的香水集團穎通控股已正式通過港交所聆訊,劍指「香水第一股」之位。作為除品牌擁有者以外,中國(包括香港及澳門)規模最大的香水集團,穎通控股擁有包括Hermès Beauty、Van Cleef & Arpels、Versace、COACH、Laura Mercier、Albion和Elegance 等72個國際知名品牌的授權,具備強大的品牌組合優勢。公司近年營收穩步增長,年度收入突破人民幣20億元,盈利能力亦持續提升,基本面表現穩健。其核心業務聚焦於中國高端香水市場,該賽道複合年增長率達15%,在消費升級與審美趨勢驅動下,市場潛力可觀。憑藉稀缺的業務定位與行業領先地位,穎通控股有望成為繼美妝新股「凍資王」毛戈平之後,引發市場高度關注的IPO焦點新股,並為投資者帶來新一輪的增長機遇。招股書披露,穎通核心業務涵蓋第三方品牌授權產品的銷售與分銷,以及為品牌授權方提供全方位市場拓展服務,包括品牌管理、定制化市場進入及擴張策略的設計與實施。截至2025年3月31日,穎通為合共72個外部品牌組合進行產品分銷及市場部署,其中61個品牌享有獨家授權或分授權。業務版圖覆蓋香水、彩妝、護膚品、個人護理產品、眼鏡及家居香氛等多元品類,形成顯著的規模優勢。值得注意的是,作為國際奢侈品牌進入中國市場的合作夥伴,穎通通過獨家授權體系獲得品牌方深度信任,進行線上線下全域營銷,這一差異化優勢持續強化穎通行業領導地位。穎通擁有廣闊的銷售及分銷網絡,線下業務覆蓋了400多個城市,有超過100個直接經營的線下POS及超過8,000個由零售商客戶經營的POS出售;線上電商管道亦不斷發力,積極佈局社交媒體和電商渠道,同時驅動免稅業務,形成全方位佈局。財務方面,穎通的經營業績穩健增長,彰顯其經營韌性。截至2025年3月31日止年度,收入分別為人民幣16.99億元、18.64億元、20.83億元;同期,錄得純利為人民幣1.73億元、2.06億元、2.27億元;毛利率亦保持穩定於50%以上。穎通挾「嗅覺經濟」東風強勢登場,配合中產消費升級與Z世代對個性化香氛的剛需,這隻「香水第一股」憑紮實品牌矩陣與全渠道運營實力,極可能複製美妝板塊上市熱潮,長線看更吃盡「嗅覺經濟」的結構性紅利,結合行業增長潛力與公司基本面,實力新股值得市場持續關注。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More

聯想控股副總裁于浩:在技術變革中錨定「長期主義」

香港, 2025年6月10日 - (亞太商訊 via SeaPRwire.com) - 新華財經香港6月9日電(記者李柏濤)近年來,全球產業鏈與科技競爭格局加速重構,人工智能、半導體、新能源等領域的博弈愈演愈烈,企業如何應對和突圍?近日,聯想控股副總裁、前瞻技術研究院院長于浩在接受記者專訪時表示,作為深度參與國際分工的科創企業,聯想控股的答案藏在「長期主義」里。「堅持自主創新不是選擇題,而是生存題。」于浩直言,從40年前中國科學院創業企業到如今橫跨多領域的科技巨頭,聯想控股堅持長期主義走的每一步都緊扣國家戰略,同時也契合自身發展和市場需求。事實證明聯想控股走長期主義路線是對的。根據最新財報,2024年聯想控股通過各項有效舉措,打了一場業績翻身仗:總營收為人民幣5128.06億元,同比增長17.61%;淨利潤為76.83億元,同比大增1119.52%;歸母淨利潤為1.33億元,較2023年的-38.74億元實現扭虧為盈。正如聯想控股董事長寧旻表態,回首四十年發展之路,中國的發展給了聯想控股巨大發展空間,懷著產業報國的初心和使命,我們將緊抓科技浪潮機遇,系統性提升科技創新能力,繼續走好創新驅動發展之路。面對國際環境劇變,于浩在採訪中透露了聯想控股的科技創新發展關鍵詞:長期研發投入、技術自主化攻堅、新興產業賦能、構建前瞻科技共創孵化體系。立足中長期 堅持自主化創新經過多年發展,聯想控股摸索出具有自身特色的科技產業化道路,這也助其發展成為世界領先的科技企業。同時,聯想控股體系持續重視科技創新與研發投入,2024年研發投入158億元,創歷史新高。于浩表示,自1984年創業起,聯想通過積累資金和辦企經驗,之後慢慢實現規模化生產,逐步建立自己的品牌、全球研發體系,最終實現了聯想特色的科技產業化。最新數據顯示,聯想控股旗下的聯想集團在今年一季度全球PC出貨量市場份額佔比為25.9%,繼續穩坐全球第一。同時,隨著多元化戰略深入推進,聯想集團業務結構也得到持續優化,截至二零二四/二五財年,非PC業務營收佔比升至47%。對於科技行業里的「卡脖子」難題,聯想控股旗下聯泓新科重點關注相關領域,正在努力推動高端新材料的國產替代;旗下的富瀚微深耕以視頻為中心的芯片設計開發,致力成為業界領先的芯片產品和技術服務提供商。其中,2010年成立的聯泓新科是從零開始構建的綠地項目,經過多年發展,已成為國家高新技術企業、全球新能源企業500強,重點關注國家需要和市場緊缺的高端新材料「卡脖子」領域,涵蓋光伏、新能源電池、生物可降解、電子特種氣體等多種領域的新材料。「我們選擇合作項目時會看早、看小,特別是在有更多破壞性創新機會的『達爾文海』領域,也就是不去跟一些創投基金去拼搶現有項目,而選擇一些大家可能沒注意到或者暫時無法顧及的項目,並做中長期佈局。」于浩說。聚焦新材料、新能源、智能傳感三大領域為推動科技創新領域的可持續發展,聯想控股專門成立了前瞻技術研究院,對趨勢性未來技術提前佈局,篩選前沿科技種子技術,與高潛力創新團隊共同設計產業化路線並完成科研成果轉化與產業落地。「前瞻技術研究院是推動科技創新戰略向縱深發展的前哨,有別於科研院校和創投機構,其縱貫從實驗室到產業化的整個創新發展生命週期。」于浩介紹,大方向上重點關注新材料、新能源、智能傳感三大領域的前瞻性技術,通過調研分析市場需求,評估備選種子技術潛力,結合產業鏈上下游和業界反饋,研判未來產業化空間。于浩表示,研究院團隊融合了「技術應用產品經理」和「產投融資財務顧問」雙重身份,以打通「從書架到貨架」「從論文到產品」「從專利到變現」的端到端轉化路徑為目標。目前,團隊已與包括北大、清華等多所高校以及中國科學院體系科研院所建立共創合作網絡,圍繞服務於未來新興產業的技術突破開展前瞻佈局。在訪談中發現,把海外領先成熟技術導入國內,助力本土企業解決痛點難點,同時借助國內巨大市場規模效應放大技術商業價值,也是該研究院的重要佈局。于浩介紹,利用積累的日系渠道資源,研究院建立了中日雙循環開放創新鏡像體系,正在借助實際項目驗證優化這個體系。其中一個典型案例是從日本引進的精細發泡技術,致力於緩解白色污染。「通過引進國際領先的新材料加工技術,在降低單位成本的基礎上,結合國內市場新應用,創新性地將核心技術轉化為新質生產力,通過技術導入實現四兩撥千斤。」于浩說。聚點成面、匯面成體,搶佔AI時代先機談及AI,于浩表示,人工智能已成為全球科技競爭的核心賽道。他對未來AI產業發展的願景是:差異化應用百花齊放,應用側反哺AI產業鏈,軟硬協同優化,技術、市場螺旋式上升,從局部數智化改造向全局「新質生產力」體系躍遷。事實上,圍繞「人工智能+」戰略,聯想控股體系在教育、醫療、交通、製造、ESG等多個垂直領域形成協同效應。智譜AI與清華大學合作的AI助教系統在多門課程中實現試點應用、被投企業深睿醫療獲批國內首個肺癌AI診斷認證、智譜AI與高通合作為汽車廠商提供端側專屬智能體解決方案、聯想集團與弘信電子集團聯合研發智能生產系統、聯想集團與生態環境部共建應對全球氣候變化和生物多樣性保護等全球性議題的AI技術應用平台...「面對AI浪潮,聯想控股選擇『全產業鏈卡位』,佈局了超270家AI產業鏈企業,形成從算法到落地的生態閉環。」于浩表示,包括地平線機器人、黑芝麻智能、小馬智行已在2024年成功登陸資本市場,所投企業中有180家獲評為國家級專精特新「小巨人」企業。于浩認為,這種「聚點成面、匯面成體」的策略,可以幫助公司在生成式AI時代佔據先機。他說,本輪以大語言模型技術路線主導的AI,已成功跨越「圖靈測試」,接下來面對的挑戰是突破「缸中之腦」,發展具身智能是通往AGI(通用人工智能)的必經之路。截至2024年底,聯想控股體系在具身智能領域投資企業近40家,涵蓋上游材料、核心零部件、智算芯片、模型算法、機器人、下游應用及解決方案等全產業鏈佈局。于浩表示,借助聯想控股的體系資源,期待孵育出越來越多優秀AI公司,不僅服務於國內市場,更要積極「出海」,提升全球影響力。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
誰將成為名留青史的「初代世界冠軍」! ACN Newswire

誰將成為名留青史的「初代世界冠軍」!

香港, 2025年6月10日 - (亞太商訊 via SeaPRwire.com) - 圓谷製作株式會社 (總公司:東京澀谷區, 總裁兼首席運營官永竹 正幸) 宣布,將為旗下的《超人力霸王卡牌遊戲》舉辦首屆全球賽事《ULTRA LEAGUE WORLD CHAMPIONSHIP 2026》!本賽事將於2026年5月9 日與10日,在日本東京太陽城展示廳B隆重舉行。在初代超人力霸王播出60週年的紀念之年,從全球23個國家和地區預選賽中勝出的「ULTRA LEAGUERS」們將齊聚一堂,透過激烈的卡牌戰鬥,爭奪「初代世界冠軍」的寶座。全球 143 位最強「Ultra Leaguers」齊聚一堂!來自世界各地的選拔賽將陸續舉行,最終僅有143位頂尖選手能晉級《Ultra League World Championship 2026》。其中部分選手將被選為「贊助選手」,其參賽旅費與費用將由官方負擔。「ULTRA LEAGUE WORLD CHAMPIONSHIP 2026」活動訊息活動日期:2026年5月9日至10日活動地點:池袋袋太陽城, World Import Mart大樓, 4樓展示廳B(日本東京都豐島區東池袋 3 丁目 1 號)賽制:雙牌組 BO3宣傳影片:https://youtu.be/OfIQdj76HfY官方網站:https://ultraman-cardgame.com/page/hk/wcs 玩家區域分布(共143位) ・亞洲地區 日本:32 中國:20 韓國:16 台灣:11 香港:11 新加坡:6 馬來西亞:6 印尼:6 越南:5 菲律賓:4 泰國:6 澳洲:4・北美地區美國、墨西哥和加拿大:12・欧洲意大利、其他欧盟国家:4※參賽名額為預估數,可能會有所變更。※請查询官方網站,了解各區域的區域預選賽日程安排。※各預選賽將使用「ULTRA LEAGUE」App。※如果主辦單位認定申請者涉嫌使用多個帳戶,則其申請和參賽資格將被取消,恕不另行通知。「ULTRA LEAGUE WORLD CHAMPIONSHIP 2026」賽事徽章本次活動的官方徽章設計為地球形球體上的盾牌,並以多彩配色象徵「ULTRA LEAGUE」之團結精神。 ULTRA LEAGUE 裁判計畫啟動 官方將於賽事前推出「ULTRA LEAGUE 裁判制度」,建立一個公平、公正、可安心參與的競技環境。通過嚴格審核與考核的合格裁判,將承擔以下職責:根據官方規則做出公平判定確保賽事順利進行即時處理現場問題向選手提供合適的協助與建議通過認證的裁判將獲得包含宣傳卡在內的專屬福利。期盼更多有志之士參與,共同推動 ULTRA LEAGUE 的健全發展。日程表裁判資格考試將於2025年8月起展開通過者將自同年11月起正式執行裁判職務裁判專屬徽章本徽章以「天秤」象徵公平,並融入溫暖氛圍,未來將用於裁判專屬的宣傳卡等物品。裁判資格考試將於2025年8月起展開通過者將自同年11月起正式執行裁判職務 《ウルトラマンカードゲーム(超人力霸王卡牌遊戲)》【官方網站】https://ultraman-cardgame.com/【註冊入口】https://ultraman-cardgame.com/page/hk/sign-up----------------------------------------------------------------------商品資訊產品名稱:超人力霸王卡牌遊戲銷售地區:日本、中國、韓國、台灣、香港、新加坡、馬來西亞、印尼、越南、菲律賓、泰國、澳洲、美國、加拿大、墨西哥、英國、義大利、西班牙、葡萄牙、荷蘭、德國、丹麥、法國 銷售通路:各地大型通路、玩具店、卡牌專賣店等----------------------------------------------------------------------【產品陣容】 《超時空の英雄たち (超時空的英雄們)(SD01)》:現正販售中 《零のキズナ (零之羈絆)(SD02)》:現正販售中 《地球の守護者たち (地球的守護者們)(BP01)》:現正販售中 《Ultraman: Rising(EXD01)》:現正販售中 《吹き荒れる紅と蒼 (緋紅與蒼藍的風暴)(BP02)》:現正販售中 《復讐と闇の輪廻 (復仇與黑暗的輪迴)(BP03)》:現正販售中 《未来へ駆けるΩ (邁向未來的Ω)(SD03)》:2025年7月25日(五)發售 《希望と光の覚醒 (希望與光的覺醒)(BP04)》:2025年8月1日(五)發售 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
UK MOD Signs Protector Support Contract with GA-ASI ACN Newswire

UK MOD Signs Protector Support Contract with GA-ASI

SAN DIEGO, CA, June 10, 2025 - (ACN Newswire via SeaPRwire.com) - The United Kingdom's Ministry of Defence has signed a support and sustainment contract with General Atomics Aeronautical Systems, Inc. (GA-ASI) for logistics and maintenance of the Protector RG Mk1 Remotely Piloted Aircraft (RPA) system. The contract - known as the UK Protector Availability and Support Solution or UK PASS - will provide ongoing support for the new Protector RPA systems supplied by GA-ASI and now being operated by the UK's Royal Air Force (RAF). The Protector RPA is based on GA-ASI's MQ-9B SkyGuardian®.Photo: Royal Air ForceUK PASS is a Direct Commercial Sale contract and includes support for the Protector program's RPA, the Certifiable Ground Control Stations and the Synthetic Training Systems."This contract marks an essential milestone in the fielding of the Protector RPA system for the RAF," said Chris Dusseault, Vice President of MQ-9B in Europe. "With the UK PASS contract in place, we can now transition from the test and development phase of the program to training the RAF flight crews for operations."UK PASS is part of GA-ASI's SkyGuardian Global Support Solutions (SGSS), which provides support for the entire MQ-9B customer base. SGSS is a shared Contractor Logistics Support (CLS) model, with resources such as labor, material, and overhead for maintenance, supply management, and other support functions required to sustain the RPA system, pooled together for use by the entire customer base. This approach provides efficiencies and a lower cost for customers."The awarding of the PASS contract marks three years of intensive work between GA-ASI and UK MOD multidisciplinary teams to turn a concept in to a reality. This has generated a first-in class sustainment solution for the Royal Air Force Protector fleet, that exploits contractor owned inventory from a global common spares pool. This contract differs from a traditional spares and repairs contract, achieving economies of scale via a multi-customer common operating model," said Group Captain Rich Cameron - Uncrewed Air System 3 Team Leader.GA-ASI's MQ-9B is the world's most advanced RPA system, delivering exceptionally long endurance and range. MQ-9B includes the SkyGuardian and SeaGuardian® models, with multiple deliveries made to the U.K.'s Royal Air Force (Protector), as well as orders from Canada, Poland, the Japan Coast Guard, the Japan Maritime Self-Defense Force, Taiwan, India, and the U.S. Air Force in support of the Special Operations Command. MQ-9B has also supported various U.S. Navy exercises, including Northern Edge, Integrated Battle Problem, and Group Sail.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle® 25M, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.Contact Information:GA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.
More

Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025

HONG KONG, Jun 9, 2025 - (ACN Newswire via SeaPRwire.com) - At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy (pMN). This marks the first time EVER001’s clinical data have been unveiled at an international academic congress. This initial unveiling of the preliminary data at an international congress focuses on pMN. The results showed encouraging signals in terms of novel mechanism, preliminary efficacy, and safety. These findings provide a solid foundation for future therapeutic strategies in proteinuric autoimmune glomerular diseases including pMN and demonstrate Everest’s advancing innovation capabilities and global development momentum.EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including IgA nephropathy (IgAN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and lupus nephritis (LN). These conditions affect over 10 million patients worldwide. There are approximately 2 million pMN patients in China alone and nearly 220,000 across the United States, Europe, and Japan. There are currently no approved therapies globally, and existing treatments rely heavily on non-specific immunosuppressants, which have limited efficacy and safety concerns, highlighting the urgent need for novel mechanism-based therapies.Everest Medicines holds global rights to EVER001 for the treatment of renal diseases. As a covalent reversible BTK inhibitor, EVER001 combines high target-binding affinity with enhanced selectivity, helping to reduce off-target toxicity seen in earlier-generation BTK inhibitors. Its favorable safety and efficacy profile supports its potential to become a new standard of care across proteinuric glomerular diseases.At ERA 2025, preliminary data from the ongoing Phase 1b/2a trial showed that EVER001 was well tolerated and demonstrated promising efficacy in patients with primary membranous nephropathy (pMN). The study enrolled 31 biopsy-confirmed pMN patients who were positive for anti-PLA2R autoantibodies and received either low or high doses of EVER001 over a 36-week treatment period, with extended follow-up for someparticipants. By week 12, anti-PLA2R autoantibody levels dropped by 62.1% in the low-dose group and 87.3% in the high-dose group. Both cohorts saw reductions of approximately 93% by week 24, with 76.9% and 81.8% of patients, respectively, achieving immunologic complete remission. For 24-hour proteinuria, the low-dose group achieved a 78.0% reduction at week 36, sustained through week 52, with 69.2% reaching clinical remission. In the high-dose group, proteinuria declined by 70.1% at week 24, with 80.0% of patients achieving clinical remission.EVER001 was generally well tolerated. No clinically significant adverse events commonly associated with covalent irreversible BTK inhibitors—such as bleeding, arrhythmia, severe infections, or liver dysfunction—were observed. Most treatment-related adverse events were mild to moderate (Grade 1–2), further supporting its long-term therapeutic potential.EVER001 is expected to generate strong portfolio synergies with Everest’s commercial-stage product, NEFECON®, the first and only fully approved etiological treatment for IgAN in China, the U.S., and Europe. NEFECON® was added to China’s National Reimbursement Drug List (NRDL) in November 2024, and has been included in the KDIGO 2024 Clinical Practice Guideline For The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV) (public review draft), making it the only targeted therapy endorsed by both international and Chinese guidelines, establishing its position as a first-line therapy. To further enhance its IgAN strategy, Everest is also developing a diagnostic test for Gd-IgA1, enabling earlier detection, more accurate disease stratification, and treatment monitoring.By integrating diagnostics and therapeutics into a unified care model, Everest is leading the transition from supportive care to precision, disease-modifying treatment for immune-mediated kidney diseases such as IgAN. This holistic strategy aims to improve disease detection and management standards and establish a comprehensive, long-term renal care platform.With EVER001 and NEFECON® advancing in parallel, Everest is driving innovation in nephrology with the goal of setting new global treatment standards. The presentation of EVER001 at ERA 2025 marks a pivotal milestone in its clinical development and demonstrates the international visibility of China-originated innovations. Everest continues to pave the way for globally competitive novel therapies to reach patients around the world. Copyright 2025 ACN Newswire via SeaPRwire.com.
More

雲頂新耀EVER001亮相ERA 2025 探索原發性膜性腎病治療新路徑

香港, 2025年6月9日 - (亞太商訊 via SeaPRwire.com) - 在第62屆歐洲腎臟協會年會(ERA 2025)上,雲頂新耀(HKEX:1952.HK)自主研發、擁有全球權益的新一代共價可逆BTK抑制劑EVER001首次以集中口頭報告形式發佈其在原發性膜性腎病(pMN)中的階段性臨床研究數據。這是EVER001首次在國際學術會議上披露相關成果,聚焦于在原發性腎小球腎炎中發病率處於第2位的原發性膜性腎病。數據顯示該產品在機制創新、初步療效以及安全性方面均展現出積極信號。此次研究的發佈為該領域未來的治療探索提供了新的臨床依據,也體現了中國創新藥企業在複雜腎病治療領域持續提升的研發能力與國際化進程。EVER001是一款創新性的共價可逆BTK抑制劑,潛在用於治療包括原發性膜性腎病等腎臟疾病在內的多種自身免疫性腎臟疾病,有望為全球逾1000萬患有原發性膜性腎病、IgA腎病、微小病變性腎病、局灶節段性腎小球硬化和狼瘡性腎炎等疾病的患者提供更多治療選擇。中國目前有約200萬原發性膜性腎病患者,歐美與日本約有近22萬患者,且逾三分之一最終進展為終末期腎病(ESRD),目前全球沒有獲批此適應症的藥物。現有方案普遍依賴非特異性免疫抑制,療效有限、安全性存疑,臨床急需機制創新的新治療方式。在此背景下,EVER001作為一款潛在的同類最佳產品,在保持高效的同時具有高選擇性,其用於原發性膜性腎病的突出臨床優勢帶來了廣闊的市場前景。根據ERA 2025大會公佈的1b/2a期研究數據,EVER001在不同劑量組均顯示出快速起效、免疫學和臨床緩解高度一致的優勢:24周時,76.9%的低劑量組患者和81.8%的高劑量組患者已達到免疫學完全緩解;低劑量組在36周蛋白尿水準較基線下降78.0%,並維持至第52周,69.2%的低劑量組患者在36周達到了臨床緩解;高劑量組則在24周即達70.1%蛋白尿下降,其中80.0%的患者已達到臨床緩解。除了優異療效,EVER001的安全性同樣突出。作為新一代共價可逆BTK抑制劑,EVER001在保持強效靶點抑制的同時,顯著降低了對EGFR、ITK等脫靶激酶的抑制風險。臨床研究未觀察到傳統共價不可逆BTK抑制劑常見的嚴重不良反應,如出血、心律失常、嚴重感染及肝功能損傷等,展現出良好的耐受性,為長期治療提供基礎,也強化其作為慢性病長期管理的競爭潛力。EVER001是雲頂新耀首個完全擁有全球開發、生產與商業化權益的管線產品。目前該產品正穩步推進多適應症臨床佈局,除pMN外,還包括IgA腎病(IgAN)、微小病變病(MCD)、局灶節段性腎小球硬化(FSGS)和狼瘡性腎炎(LN)等免疫性腎病領域,具備全球市場潛力,並已被納入公司國際化戰略重點,未來有望通過授權合作、國際註冊等多元路徑實現「自研出海」。在腎病戰略板塊中,EVER001與雲頂新耀另一核心產品耐賦康®正逐步形成機制互補與適應症覆蓋的協同效應。耐賦康®是全球首個且唯一在中國、美國和歐洲獲得完全批准的IgA腎病對因治療藥物,2024年11月納入中國國家醫保目錄,並先後被納入改善全球腎臟病預後組織(KDIGO)發佈的《2024版KDIGOIgA腎病和IgA血管炎臨床管理實踐指南(公開審查版)》,以及《中國成人IgA腎病及IgA血管炎臨床實踐指南(預審版本)》,確立其一線治療基石地位。為進一步提升從早篩、治療到長期管理的系統能力,公司正同步推進Gd-IgA1診斷試劑的開發,助力IgAN等慢性病實現更早識別、更精准分型及療效監測。通過「診斷+治療」全流程一體化佈局,雲頂新耀正推動IgAN等免疫相關腎病從支持性治療邁向精准對因管理,系統提升疾病識別效率與治療規範性,為腎病構建具長期價值的綜合解決方案平台。在全球腎病領域臨床挑戰與創新機遇並存的當下,雲頂新耀正通過耐賦康®與EVER001雙路徑並進的策略,推動中國創新藥構建全球治療新標準。ERA 2025上EVER001的亮相,不僅標誌其臨床開發進入關鍵節點,也展現了中國自研藥物在國際學術平台上的影響力,為中國原研藥「走出去」提供範例,也為全球患者帶來機制創新、療效優異的治療新方案。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
光大控股成功發行30億元人民幣熊貓中期票據 ACN Newswire

光大控股成功發行30億元人民幣熊貓中期票據

香港, 2025年6月9日 - (亞太商訊 via SeaPRwire.com) - 6月5日,光大控股(股份代號:165.HK)2025年度第一期中期票據在中國銀行間市場成功發行,發行規模30億元人民幣,票面利率2.09%,創光大控股歷史債券發行票面利率新低。本次發行獲得了銀行及非銀機構投資者的踴躍認購,全場認購倍數2.6倍,邊際認購倍數2.8倍,充分體現出市場機構投資者對公司高質量發展的認可與支持。公司選用光大證券擔任牽頭主承銷商及簿記管理人,選用中國銀行、浦發銀行、中信證券、中國工商銀行、中信銀行擔任聯席主承銷商,強強聯合、通力合作、攜手共贏,達成本次發行工作的圓滿成功。本次發行進一步降低融資成本,優化公司的債務結構。光大控股將繼續發揮跨境資管平台優勢,持續推進業務高質量發展,服務中國經濟可持續發展。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
Champion REIT Presents ‘Lupus Reimagined’ Art Exhibition, Connecting Community Through Art ACN Newswire

Champion REIT Presents ‘Lupus Reimagined’ Art Exhibition, Connecting Community Through Art

HONG KONG, Jun 6, 2025 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (the “Trust”) (Stock Code: 2778), owner of Three Garden Road and Langham Place, has partnered with “My Lupus Diary” (MLD), the first multimedia lupus awareness organisation in Hong Kong, and Eaton Club, a premium coworking space providing venue support, to present “Lupus Reimagined” Art Exhibition at its properties. The exhibition features the original artworks of lupus patients, expressing their journey in facing physical and emotional challenges via the universal language of art. This initiative aims to enhance public awareness and understanding of health, diversity and inclusion. The exhibition features diverse artistic expressions including photographs, paintings, headdresses, and installation art pieces for public viewing. A highlight piece is a warrior armour made from two months' worth of medication taken by one of the patients, symbolising how lupus patients, despite requiring long-term medication, remain strong warriors in their battle against the disease.Champion REIT has long upheld the principles of physical, mental and spiritual health and sustainability, fostering long-term partnerships with the community hoping to harness the synergies from cross-sector collaboration to create a shared social environment. As the principal sponsor of the exhibition, the Trust not only provides a creative platform for patients to express themselves, but also helps enhance public awareness and care for those suffering from rare diseases, as well as fulfilling its corporate responsibility to promote social inclusion.The “Lupus Reimagined” Art Exhibition features the artistic creations of nine lupus warriors, who showcase their emotional transformation, struggles, and growth through various artistic approaches. A highlight of the exhibition is an art photography series co-created by MLD and four well-known Hong Kong models - Janet Ma, Angie N, Ana R and Amanda S. The models wear headdresses created by the lupus patient, symbolising strength and transformation, visually representing the inner resilience of those living with lupus and inspiring society to reframe how it perceives patients’ unique experiences and the value of life.Ms Sapphire Shen, MLD founder, said, “Our three founders are all lupus patients. We hope to use art as a bridge to break down social stigma and misunderstanding, so that society can truly understand the challenges patients face and the courage they afford, thereby helping build a more empathetic and inclusive society.”Earlier on May 10 – World Lupus Day, a series of educational talks on the latest lupus treatments and awareness-raising events were hosted at Eaton Club, Three Garden Road. Building on this successful launch, the art exhibition was officially unveiled to the public at Three Garden Road in May and has been moved to the Langham Place Office Tower in June. A special sharing session will be held on 8 June, where founder Ms Sapphire Shen and the participating models will engage with visitors and patients to share their experiences and stories. In recent years, the Langham Place Office Tower has actively promoted the “6 Dimensions Wellness” concept, a new ecosystem with physical, emotional, intellectual, social, spiritual and financial wellness as its core, providing tenants with a comprehensive physical, mental and spiritual health support platform. Langham Place also launched the “6D Wellness” YouTube channel (www.youtube.com/@6dwellnesslp) in line with that strategy, inviting professionals and guests to share practical health information every week, injecting positive social value into the community.Ms Christina Hau, Chief Executive Officer of Champion REIT, said, “We firmly believe that sustainable business development is inseparable from close community engagement and mutual growth. Thus, the Trust has always prioritised physical, mental and spiritual health, and sustainable development as its core strategies, and has been active in building long-term partnership with the community to promote inclusion and social collaboration. As the venue sponsor of this art exhibition, we hope to offer a platform for different groups to express themselves and gain understanding, allowing more diverse voices to be heard. We will continue to give back to society with concrete actions and contribute to building a more inclusive, harmonious and healthy social environment.”In recent years, the Trust has actively collaborated with various social organisations to create shared value and achieve mutual success for all parties. It held the first “ESG Week” in 2024, partnering with stakeholders to host activities on climate resilience, social innovation and sustainable living. It has also teamed up with the Fullness Social Enterprises Society to invite local social enterprises showcase innovative solutions addressing social issues, and promote social inclusion, cultural diversity, and cross-sector collaboration. To reinforce its ESG commitment, the Trust will hold its annual flagship event “ESG Gala” in late July this year, featuring a broader range of activities co-created with partners to uphold the core values of physical, mental and spiritual health, while amplifying the voices of diversity and inclusion across the society."Lupus Reimagined" 2025 World Lupus Day Art ExhibitionPublic ExhibitionVenue: Lobby, 5th Floor, Langham Place Office Tower, 8 Argyle Street, Mong Kok, KowloonDate: 2 June - 30 June 2025Time: 09:00 - 20:00 (Monday to Sunday)Public Sharing SessionVenue: Lobby, 5th Floor, Langham Place Office Tower, 8 Argyle Street, Mong Kok, KowloonDate: 8 June 2025Time: 12:30 - 17:30 (Sunday)Photo caption:Connecting the community through art, Champion REIT organised the “Lupus Reimagined” Art Exhibition at Langham Place Office Tower, featuring the original artwork of lupus patients.The “Lupus Reimagined” Art Exhibition features the artistic creations of nine lupus warriors, who showcase their emotional transformation, struggles, and growth through various artistic approaches. The installation art piece, crafted from two months' worth of a patient's medication – around 720 pills in total, tells the story of every lupus warrior's battle against the disease. Artist Ms Christy Cheung poses with her artwork.Founder of My Lupus Diary, Ms Sapphire Shen discusses the exhibition's artistic vision and inclusive message.CreditsPresented by My Lupus Diary @mylupusdiaryProducer & Creative Director: Sapphire Shen @shensapphireArt Director & Photographer: Kim Lo @lamma @klw_hkMakeup Artist: Kae Li @kae.liiiHair Stylist: Brian Lee @brianlee_hmuaSpecial Thanks: Aarya Kalathiya, Crystal. SAbout Champion REIT (2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income-producing office and retail properties. The Trust focuses on Grade-A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023.Website: www.championreit.comAbout My Lupus DiaryMy Lupus Diary Limited (MLD) was co-founded by three lupus patients in 2017 as an online patient support platform. We share and exchange information, tell our stories, organise activities, build a lupus community and raise awareness of the illness. As a non-profit organisation now, we are committed to improving the quality of life of the lupus community through empowerment, education and advocacy.Media Enquiries:Strategic Financial Relations LimitedVicky LeeTel: 2864 4834Email: vicky.lee@sprg.com.hkCynthia NgTel: 2114 4952Email: cynthia.ng@sprg.com.hkSophia LeiTel: 2864 4873Email: sophia.lei@sprg.com.hkWebsite: www.sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.
More